8-K: Traws Pharma's Tivoxavir Marboxil Shows Promise in Bird Flu Treatment: ICAR Presentation Highlights Positive Data

Traws Pharma announces positive data presented at ICAR 2025 for tivoxavir marboxil (TXM), an investigational one-dose influenza therapy, demonstrating potential for the treatment of H5N1 avian influenza.

Summary

• Traws Pharma presented data at the International Conference on Antiviral Research (ICAR 2025) on March 20, 2025, showcasing the potential of tivoxavir marboxil (TXM) for treating H5N1 avian influenza.
• The poster presentation highlighted positive data from laboratory, preclinical, and Phase 1 studies.
• Preclinical studies in a rodent challenge model showed 100% survival in mice treated with TXM, while all untreated animals died by day 6.
• TXM also demonstrated potent suppression of influenza A, B, and C viruses, including baloxavir-resistant strains, with sub-nanomolar potency against H5N1.
• Phase 1 data in healthy volunteers showed that a single dose of TXM maintained plasma blood levels at EC90 for approximately 3 weeks, with good tolerability.
• The company plans to meet with the FDA to discuss next steps, including a potential accelerated path to approval.
• A virtual investor event is scheduled for March 31, 2025, to provide further updates on Traws' antiviral programs.

Sentiment

Score: 8

Explanation: The document presents positive preclinical and Phase 1 data for tivoxavir marboxil, suggesting potential for bird flu treatment. The company is also pursuing an accelerated approval pathway with the FDA, which further contributes to the positive sentiment.

Positives

• Tivoxavir marboxil (TXM) demonstrated 100% survival in a rodent challenge model infected with H5N1.
• TXM showed potent suppression of influenza A, B, and C viruses, including baloxavir-resistant strains.
• Phase 1 trial results indicate good tolerability and sustained therapeutic drug levels for approximately 3 weeks after a single dose of TXM.
• The company is actively pursuing an accelerated approval pathway with the FDA.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the success and timing of clinical trials, regulatory requirements, and the extent of the spread and threat of bird flu.

Future Outlook

Traws Pharma plans to meet with the FDA to align on next steps, including the potential for an accelerated path to approval for tivoxavir marboxil as a treatment for bird flu and seasonal influenza.

Management Comments

• C. David Pauza, PhD, Chief Science Officer of Traws Pharma, believes that an effective antiviral agent for bird flu needs to potently suppress native and resistant viruses and provide protection against mortality and viral disease, with good overall tolerability and ease of use.
• Werner Cautreels, PhD, Chief Executive Officer of Traws Pharma, looks forward to updating investors on Traws' antiviral programs during a virtual event on Monday, March 31, 2025.

Industry Context

The development of tivoxavir marboxil addresses the growing concern over emerging respiratory viral diseases, particularly avian influenza, and the need for effective antiviral treatments. The seasonal influenza market represents a multi-billion dollar opportunity.

Comparison to Industry Standards

• The document mentions Baloxavir, a cap-dependent endonuclease inhibitor, as a comparator, noting that TXM demonstrated greater potency against Baloxavir-resistant strains.
• The document references a study by Mostafa, A., Barre, R.S., Allue-Guardia, A., et al. (2025) Emerging Microbes and Infections, which provides context on the characteristics of influenza viruses.
• The document references a study by Chesnokov, A., et al. 2024. Antimicrob. Agents Chemother. 68: e0172723 which provides context on the characteristics of influenza viruses.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of TXM could provide a new treatment option for patients at risk of bird flu.
• The company's progress could lead to job creation and economic growth.

Next Steps

• Traws Pharma plans to meet with the FDA to discuss next steps for tivoxavir marboxil, including a potential accelerated path to approval.
• The company will host a virtual investor event on March 31, 2025, to provide further updates on its antiviral programs.

Key Dates

Keywords

tivoxavir marboxil, TXM, bird flu, H5N1, influenza, antiviral, Traws Pharma, ICAR 2025, Phase 1 trial, rodent challenge model